Collplant Biotechnologies Ltd Stock Price, News & Analysis

CollPlant Biotechnologies (Nasdaq: CLGN) announced it will report third quarter 2025 financial results on Wednesday, November 26, 2025, before the U.S. market open. The company develops non-animal-derived rhCollagen products for tissue regeneration and medical aesthetics. Investors can expect the company to release results and any accompanying commentary or materials on that date.

CollPlant (Nasdaq: CLGN) announced an expansion of its North American distribution through a new U.S.-based logistics center, scheduled to become operational this quarter (announcement dated Oct 27, 2025).

The hub will provide full cGMP-compliant storage and distribution, serve as a clinical supply depot, and support rhCollagen and BioInk product lines in the U.S. and Canada. Facility features include cGMP-controlled environments, cloud-based temperature monitoring, advanced emergency backup, AI-powered security, and remote inventory management.

Management said local inventory and improved logistics are expected to increase efficiency, reduce shipping time, and strengthen support for customers and clinical partners in North America.

CollPlant (Nasdaq: CLGN) announced that a head-to-head study by Technion's Levenberg Lab found its rhCollagen-based bioink Collink.3D™ outperformed Matrigel® on key lab metrics. Collink.3D™ reportedly showed enhanced mechanical strength, elasticity, and stability, supporting organized and long-lasting tissue formation in a reproducible, animal-free format.

The release highlights potential application in tissue engineering, regenerative medicine, and drug discovery and notes the global basement membrane matrix market was ~$96M in 2024, projected to reach $201M by 2031 (CAGR 11.2%).

CollPlant (NASDAQ: CLGN) said Mayo Clinic researchers developed a first‑in‑kind fully humanized 3D bioprinted human skin model using CollPlant's plant‑derived recombinant human collagen (rhCollagen) bioink, announced Oct. 16, 2025.

The model combines rhCollagen bioinks with human fibroblasts, melanocytes and keratinocytes and is integrated into a skin‑on‑a‑chip system to evaluate topical and transdermal drug delivery as a non‑animal preclinical platform. Claimed advantages include high‑throughput production, personalized human skin models at scale, reduced animal testing, and potential use in cosmetic and pharmaceutical testing, disease modeling, drug development and regenerative medicine.

CollPlant Biotechnologies (NASDAQ: CLGN) has announced positive results from non-clinical studies of its innovative photocurable dermal and soft tissue filler. The company's breakthrough product combines hyaluronic acid with modified rhCollagen to provide both immediate and long-lasting aesthetic benefits.

The novel filler is administered as a viscoelastic gel through a fine needle, allowing precise sculpting that is then stabilized using CollPlant's proprietary illumination device. Key findings include successful one-year durability studies and positive biocompatibility assessments meeting international standards. The company is now advancing towards clinical trials and optimizing its manufacturing processes.

CollPlant Biotechnologies (NASDAQ: CLGN) has announced the expansion of its European distribution network for Vergenix™ STR through a new agreement in Poland. The product, based on CollPlant's rhCollagen technology, is designed to treat various tendinopathies by combining with platelet-rich plasma (PRP) to form a scaffold that promotes tendon healing.

Vergenix™ STR targets multiple indications including tennis elbow, rotator cuff injuries, patellar tendinopathy, Achilles tendon injuries, and hand tendon repairs. The product creates a gel matrix that enables localized, sustained release of growth factors at injury sites. CollPlant expects to deliver the first shipment to its Polish distributor by the end of 2025.

CollPlant Biotechnologies (Nasdaq: CLGN) announced its participation in the International Conference on Biofabrication 2025, scheduled for September 14-17, 2025, in Warsaw, Poland. The company will deliver two presentations: "rhCollagen Bioinks for Biofabrication" on September 16th during the Industrial Session, and "Mechanical Computational Modeling and Simulation of Biodegradable Implants" on September 17th.

The company will showcase its rhCollagen platform and biofabrication applications at an exhibition booth. CollPlant's rhCollagen-based bioinks are designed for 3D bioprinting applications in medical research, featuring controlled rheology, non-animal safety profile, biocompatibility, and tunable mechanical properties.

CollPlant Biotechnologies (NASDAQ: CLGN), a company focused on regenerative and aesthetics medicine using non-animal-derived recombinant human collagen technology, has announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference.

The conference will take place on September 8-9, 2025, at the Lotte New York Palace Hotel. Senior management will be available for one-on-one meetings with investors, which can be arranged through H.C. Wainwright representatives or via meetings@hcwco.com.

CollPlant Biotechnologies (NASDAQ:CLGN) reported Q2 2025 financial results and provided updates on its key programs. The company recorded revenues of $179,000 in Q2 2025, down from $249,000 in Q2 2024, with a net loss of $3.3 million. For the first half of 2025, revenues reached $2.2 million, primarily due to a $2 million milestone payment from AbbVie.

Key developments include advancing its photocurable dermal filler program toward clinical stage, progress in regenerative breast implants development with successful 3D bioprinting of 200cc commercial-size implants, and expansion of Vergenix™ STR distribution into new markets. The company strengthened its financial position through a $3.6 million registered direct offering and ended Q2 with $11.4 million in cash.

CollPlant also appointed Bowman Bagley as VP of Commercial North America and expanded its agreement with STEMCELL Technologies for broader use of its rhCollagen technology.